In contrast, IDO-1 inhibitor in association with p53-DC vaccine has been shown to increase the IFN γ-producing CD8 and the IL-2-producing CD4 T cell response in phase 1/2 study of metastatic BC patients, although it did not increase the objective response rate (169). This evidence concerns the gene IDO1 and breast cancer.